Bavarian Nordic maintains guidance for 2021

In its Thursday Q1 report, Bavarian Nordic states that it is maintaining its guidance for 2021. It expects DKK 1.9-2.2bn in revenue and an operating result of DKK 100-250m.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic closed its first quarter with growth on the top line though negative results in operations and on the bottom line have also increased significantly.

The company is advancing in spite of waning sales from the vaccines Rabipur/Rabavert for rabies and Encepur for tick-borne encephalitis.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs